[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cardiol Therapeutics (CRDL)

Cardiol Therapeutics (CRDL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 153,189
  • Shares Outstanding, K 111,817
  • Annual Sales, $ 0 K
  • Annual Income, $ -24,200 K
  • EBIT $ -25 M
  • EBITDA $ -24 M
  • 60-Month Beta 0.77
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 12.05

Options Overview Details

View History
  • Implied Volatility 184.31% (+16.63%)
  • Historical Volatility 81.12%
  • IV Percentile 5%
  • IV Rank 12.46%
  • IV High 1,171.62% on 10/14/25
  • IV Low 43.77% on 03/16/26
  • Expected Move (DTE 13) 0.0425 (3.10%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 49
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 4,450
  • Open Int (30-Day) 4,229
  • Expected Range 1.3275 to 1.4125

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.06
  • Number of Estimates 2
  • High Estimate $-0.06
  • Low Estimate $-0.07
  • Prior Year $-0.07
  • Growth Rate Est. (year over year) +14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2800 +7.03%
on 04/29/26
1.7100 -19.88%
on 04/22/26
-0.0300 (-2.14%)
since 04/01/26
3-Month
0.8974 +52.66%
on 03/20/26
1.7100 -19.88%
on 04/22/26
+0.4193 (+44.10%)
since 01/30/26
52-Week
0.8800 +55.68%
on 12/01/25
1.7100 -19.88%
on 04/22/26
+0.2500 (+22.32%)
since 05/01/25

Most Recent Stories

More News
Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program

TORONTO , April 28, 2026 /CNW/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a late-stage life sciences company advancing anti-inflammatory and...

CRDL.TO : 1.84 (-1.08%)
CRDL : 1.3700 (-0.72%)
Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program

TORONTO , April 28, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a late-stage life sciences company advancing anti-inflammatory...

CRDL.TO : 1.84 (-1.08%)
CRDL : 1.3700 (-0.72%)
Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart

Toronto, Ontario--(Newsfile Corp. - April 14, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development...

CRDL.TO : 1.84 (-1.08%)
CRDL : 1.3700 (-0.72%)
Cardiol Therapeutics Announces Year-End 2025 Update on Operations

Initiated pivotal Phase III MAVERIC trial of CardiolRxâ„¢ in recurrent pericarditis and surpassed 50% patient enrollment, with full enrollment expected in Q2 2026.Reported positive Phase II ARCHER data...

CRDL.TO : 1.84 (-1.08%)
CRDL : 1.3700 (-0.72%)
Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference

Toronto, Ontario--(Newsfile Corp. - February 25, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development...

CRDL.TO : 1.84 (-1.08%)
CRDL : 1.3700 (-0.72%)
Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure

Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development...

CRDL.TO : 1.84 (-1.08%)
CRDL : 1.3700 (-0.72%)
Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million

Toronto, Ontario--(Newsfile Corp. - January 23, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development...

CRDL.TO : 1.84 (-1.08%)
CRDL : 1.3700 (-0.72%)
Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million

Toronto, Ontario--(Newsfile Corp. - January 16, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development...

CRDL.TO : 1.84 (-1.08%)
CRDL : 1.3700 (-0.72%)
Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

Clinical trial infrastructure fully operational in the U.S. with more than 15 leading cardiovascular centers actively enrolling patients.Activation of additional top-tier clinical sites in Europe and Canada...

CRDL.TO : 1.84 (-1.08%)
CRDL : 1.3700 (-0.72%)
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions

(December 1, 2025) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company advancing anti-inflammatory and

CRDL.TO : 1.84 (-1.08%)
CRDL : 1.3700 (-0.72%)

Business Summary

Cardiol Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease. The company's lead product consist CardiolRx(TM). Cardiol Therapeutics Inc. is based in Oakville, ON.

See More

Key Turning Points

3rd Resistance Point 1.4333
2nd Resistance Point 1.4067
1st Resistance Point 1.3883
Last Price 1.3700
1st Support Level 1.3433
2nd Support Level 1.3167
3rd Support Level 1.2983

See More

52-Week High 1.7100
Fibonacci 61.8% 1.3929
Last Price 1.3700
Fibonacci 50% 1.2950
Fibonacci 38.2% 1.1971
52-Week Low 0.8800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.